Apomorphine delivered in the paraventricular nucleus of the hypothalamus (PVN) induces penile erection in rats, suggesting a role of dopaminergic projection to the PVN in the control of penile erection. We assessed whether the selective inhibitor of monoamine oxidase B, selegiline, could enhance the erectile activity induced by dopamine delivery in the PVN. Intracavernous and blood pressure (ICP and BP) were monitored in anesthetized rats to quantify ICP rises (number and percentage of ICP maximum=mean BP (ICPmax=BP Â 100)) elicited by 10 mg dopamine injection in the PVN after saline or 3 mg=kg i.v. selegiline (8 rats per group). The number of ICP rises (mean AE s.d.: 4.5 AE 2.9 vs 1.4 AE 1.9; P ¼ 0.017) and their ICPmax=BP Â 100 (49 AE 8% vs 34 AE 9%; P ¼ 0.015) were significantly greater upon dopamine injection in the PVN than upon vehicle. Compared to saline i.v., 3 mg=kg selegiline pretreatment significantly increased the number of ICP rises induced by dopamine injection in the PVN (9.4 AE 2.6 vs 4.5 AE 2.9; P < 0.001), without affecting their amplitude. This suggests that drugs potentiating dopaminergic responses in the central nervous system might enhance proerectile commands of supraspinal origin.
Introduction
Peripheral delivery of apomorphine, a non-specific D1-like as well as D2-like dopamine receptor agonist, induces penile erections in rats by acting in the paraventricular nucleus of the hypothalamus (PVN). 1 Injection of doses of apomorphine as low as 5 ng in the PVN can induce penile erections in conscious rats. 2 Conversely, penile erections induced by peripheral delivery of apomorphine are antagonized by a preceding injection of SCH23390, a D1-like receptor antagonist or sulpiride, a D2-like receptor antagonist, in the PVN of anesthetized rats. 3 This suggests that dopaminergic release within the PVN play a key role in the control of penile erection.
A corollary of the aforementioned statement is that indirect dopaminergic agonist might have some proerectile activities. Selegiline hydrochloride (registered as L-deprenyl) is a selective monoamine oxidase inhibitor B (MAO B), which has been successfully used alone or as an adjunctive treatment to 3,4-dihydroxy-L-phenylalanine (L-DOPA, the precursor of dopamine) in Parkinson's disease. 4 Experimental data suggest that selegiline enhances dopaminergic responses in rats. For example, pretreatment with selegiline potentiated individual neuronal responses of single striatal neuron to iontophoretically applied dopamine in vivo. 5 It also increased contralateral rotations induced by intraperitoneal L-DOPA injections in rats with unilateral lesion of the substantia nigra. 6 The mechanisms responsible for the effect of selegiline on dopaminergic responses differ in rats and humans. In rats, catabolism of dopamine is not affected by inhibition of MAO B by selegiline, probably because of a high ratio of MAO A=MAO B concentration. 5,7 -10 The enhanced dopaminergic responses are therefore not due to an increased availability of dopamine caused by a decreased degradation by MAO B. The ability of selegiline to increase dopaminergic responses in rats has been explained by the amphetamine-like properties of L-methamphetamine, a major metabolite of selegiline. 11, 12 It was also proposed that in the rat brain selegiline could increase the level of b-phenylethylamine, an endogenous trace amine which potentiates neuronal response to dopamine. 5,13 -15 Taking into account the potentiating activity of selegiline on dopaminergic responses in rats, we hypothesized that erectile responses induced by central dopamine could be enhanced by systemic selegiline pretreatment. We therefore assessed the ability of selegiline delivered intravenously (i.v.) to enhance erectile responses induced by dopamine injections in the PVN in anesthetized rats.
Materials and methods
Thirty two adult male Sprague-Dawley rats (CharlesRiver, St-Aubin-lès-Elbeuf, France) weighing 200 -250 g, were anesthetized with an intraperitoneal injection of urethane (1.2 g=kg, Sigma-Aldrich, StQuentin-Fallavier, France). Their temperature was maintained at 37 C using a homeothermic blanket. Rats were tracheotomized to prevent aspiration of saliva, and, when required, to perform artificial ventilation. The carotid artery and jugular vein were catheterized with polyethylene tubings filled with heparinized saline (25 IU=ml) to record the mean systemic arterial blood pressure (BP) via a pressure transducer (Elcomatic 750, Glasgow, UK) and inject drugs into the bloodstream, respectively. The prepuce was circumcised and the penis denuded of skin. The animal was placed on a stereotaxical apparatus. A heparinized saline-filled catheter connected to a pressure transducer (Elcomatic EM 750, UK) was inserted in the left corpus cavernosum to record intracavernous pressure (ICP).
Selegiline (Sigma-Aldrich) was dissolved in saline and dopamine (Sigma-Aldrich) in saline supplemented with 0.05% ascorbic acid to retard oxidation. Intravenous injection of selegiline (3 mg=kg) or the corresponding vehicle injection was performed 5 min after the start of recording and 10 min prior to the PVN injection. Dopamine (10 mg in 1 ml) or vehicle were injected into the PVN (stereotaxic coordinates: 0.3 mm posterior to bregma; 0.4 mm lateral to the midline; 8.4 mm below the skull surface, with the upside of the incisor bar at the level of the interaural line) over 1 -2 min using a 1 ml Hamilton microsyringe. Eight rats were included in each of the 4 groups (2 groups injected with selegiline i.v. and with either dopamine or the corresponding vehicle in the PVN, 2 groups injected with saline i.v. and with either dopamine or the corresponding vehicle in the PVN). BP and ICP were recorded for 30 min after the injection of dopamine. Evans blue was microinjected for histological identification of the injection site at the end of the experiment. After sacrifice, the brain was removed and serially cut in 20 mm thick sections on a microtome. One in 5 slices was mounted on gelatinized slides and dyed with cresyl violet. Rats for which the tip of the injection was outside the PVN were eliminated from the study.
BP and ICP tracings were analyzed retrospectively using software designed in our laboratory. Only ICP rises with a maximal value superior to the sum of the average þ 3 standard deviations of the ICP recorded during the 5 min before the injection of drug or vehicle were quantified. Such ICP rises were considered as erectile events. Latency was the time separating the beginning of the PVN injection from the first ICP rise. ICPmax=BP Â 100 corresponded to the percentage of the ratio: maximal value reached by ICP during the rise (mm=Hg)=mean BP(mm=Hg) for the duration of the ICP rise. The area under the curve of ICP rise divided by the mean BP, termed AUC=BP (s) and the sum of the AUC=BP (s) of all the ICP rises, which represents an index of overall erectile activity, were also calculated for each rat. All parameters were averaged per rat, except the sum of AUC=BP, and then per treatment. Rats which did not display any ICP rise (non-responder rats) during the recording were attributed the value 0 for the sum of AUC=BP and number of ICP rises. For non-responder rats, ICPmax=BP Â 100 and AUC=BP were considered as missing data for the statistical analysis.
Data were compared using two way analysis of variance (ANOVA) followed by post-hoc analysis with the Student -Newman -Keuls method when required. All tests were conducted using SigmaStat 1 software, version 2.03 (SPSS, Erkrath, Germany). Differences were considered significant when P < 0.05. All results are expressed as mean AE standard standard deviation (s.d.).
Results
In the groups injected with vehicle in the PVN, selegiline i.v. injection resulted in an increase in the number of rats presenting at least one ICP rise compared to saline i.v. injection (7=8 vs 3=8 respectively). All rats displayed at least one ICP rise in the groups injected with 10 mg dopamine in the PVN. Original recordings showings the effect of dopamine injection in the PVN after i.v. pretreatment with either saline or 3 mg=kg selegiline are displayed in Figure 1 .
Two way ANOVA revealed a significant effect of dopamine injection in the PVN on the mean number and sum of AUC=BP of the ICP rises (F[1,28] ¼ 30. 13 and 33.91 respectively, P < 0.001 for both), as well as on ICPmax=BP Â 100 and latency (F[1,22] ¼ 22.94, P < 0.001 and 4.39, P ¼ 0.048, respectively). There was also a significant effect of selegiline pretreatment on Post-hoc analysis within factor with StudentNewman -Keuls' test allowed analysis of: 1) the effects of dopamine injection in the PVN after saline i.v. pretreatment; 2) the effects of selegiline pretreatment on saline PVN delivery; and 3) the effect of selegiline pretreatment on dopamine PVN delivery.
Dopamine injection in the PVN
The proerectile activity of dopamine delivered in the PVN was analyzed by comparing the 2 groups pretreated with i.v. saline (Figure 2 ), and injected with either 10 mg dopamine or the corresponding vehicle in the PVN. The mean number (Figure 2A ) and ICPmax=BP Â 100 ( Figure 2C ) of the ICP rises were significantly greater upon 10 mg dopamine delivery compared to the corresponding vehicle injection (4.5 AE 2.9 vs 1.4 AE 1.9, P ¼ 0.017, and 49 AE 8% vs 34 AE 9%, P ¼ 0.015, respectively). The mean AUC=BP of the ICP rises was also increased in the group injected with dopamine compared to its control group (14.7 AE 9.3 s vs 9.1 AE 4.6 s respectively, Figure 2B ), but this was not significant. The increase of the number and amplitude of the ICP rises upon 10 mg dopamine injection in the PVN was reflected in a four fold increase of the sum of AUC=BP (52 AE 27 s in the dopamine group vs 13 AE 21 s in the control group, P ¼ 0.031, Figure 2D ). The latency of the first ICP rise was significantly decreased by dopamine injection in the PVN (138 AE 55 s in the dopamine group vs 362 AE 90 s in the control group, P ¼ 0.046, Figure 2E ). Dopamine injection in the PVN had no effect on blood pressure at a dose of 10 mg. Anesthetized rats were injected with either selegiline (3 mg=kg) or saline i.v., followed 10 min later with vehicle or dopamine (10 mg) injection in the PVN. Eight rats were used in each condition. ICP rises were quantified for 30 min after the onset of the PVN injection. *P < 0.05 and **P < 0.01 refers to post-hoc analysis with Student -Newman -Keul's test after 2 way ANOVA. Stars above horizontal bars indicate a significant effect of selegiline i.v. treatment for a given PVN injection (eg in A, selegiline injection significantly increased the number of ICP rises induced by dopamine injection in the PVN). Stars above mean standard deviation refer to a significant effect of dopamine injection in the PVN for a given i.v. injection (eg in C, the ICPmax=BP Â 100 of the ICP rises was significantly increased by dopamine injection in the PVN in either vehicle or selegiline treated rats compared to vehicle injection in the PVN).
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In rats injected with vehicle in the PVN, selegiline 3 mg=kg i.v. resulted in a significant reduction of the latency of the first ICP rise compared to i.v. saline (117 AE 114 s vs 362 AE 438 s respectively, P ¼ 0.033, Figure 2E ). AUC=BP and ICPmax=BP Â 100 were not affected ( Figure 2B and C) . The mean number of ICP rises and sum of AUC=BP tended to be increased by i.v. selegiline compared to i.v. saline (Figure 2A and D) . It is noteworthy that when only rats displaying at least one erectile event are considered, the number of ICP rises in the saline and selegiline i.v. groups injected with vehicle in the PVN were similar (3.6 AE 0.6 and 3.4 AE 2.0 respectively). Selegiline 3 mg=kg i.v. induced a transient decrease in blood pressure, which returned to its baseline value after 3 to 4 min.
Selegiline i.v. and dopamine injection in the PVN
The ability to selegiline to enhance central dopamineinduced erectile activity was analyzed by comparing results obtained in rats injected with 10 mg dopamine in the PVN and pretreated with i.v. saline or selegiline (grouped empty and filled bars on the right of each graph in Figure 2 ). Selegiline i.v. 3 mg=kg 10 min prior to 10 mg dopamine injection in the PVN significantly enhanced the number (9.4 AE 2.6 vs 4.5 AE 2.9, Figure 2A ) and the sum of AUC=BP (132 AE 54 vs 52 AE 27, Figure 2D ) of ICP rises compared to i.v. saline injection (P < 0.001 for both). AUC=BP and ICPmax=BP Â 100 of the ICP rises induced by dopamine injection in the PVN were barely affected by i.v. selegiline pretreatment ( Figure 2B and C).
Discussion
We have shown in this study that the injection of 10 mg dopamine in the PVN is a powerful inducer of erectile responses in the anesthetized rats. This confirms the very likely involvement of the dopaminergic incerto-hypothalamic pathway in the control of penile erection which has been mainly established using the D1=D2-like dopamine receptor agonist apomorphine. 1 In preliminary trials, we failed to elicit consistent erectile responses by injecting less than 1 mg dopamine in the PVN. Eventually, 10 mg dopamine induced consistent erectile activity, equivalent to the one observed after injection of 500 ng apomorphine in the PVN (not shown). The reasons to explain the difference in the efficacy of apomorphine over dopamine are: 1) the greater affinity of apomorphine (approximately 10 times) for dopamine receptors than dopamine itself; and 2) the considerable catabolic inactivation and reuptake of extracellular dopamine after its release in the extracellular space, which considerably reduces its bioavailability compared to apomorphine. 16, 17 We hypothesized that drug enhancing dopaminergic responses, such as selegiline, should increase the erectile activity induced by dopamine injected in the PVN. Such dopamine injection is supposed to mimic the release of dopamine occurring in the PVN upon sexual arousal in physiological conditions. Accordingly, a significant and consistent enhancement of the number of erectile events induced by dopamine injected in the PVN was observed after pretreatment with 3 mg=kg i.v. selegiline, a dose which selectively inhibits MAO B in rats. 5 In rats, the potentiation of dopaminergic response by selegiline is likely to be caused by an increase in the availability of b-phenylethylamine, a trace amine which has been shown to be a specific substrate for monoamine oxidase B and to potentiate dopaminergic responses. 5,13 -15 Our results are in agreement with several studies reporting an enhancement of mating performance in old and sexually sluggish rats treated with deprenyl, although Ferrari and Giuliani could not provide evidence for an enhancer effect of selegiline on copulatory performance in sexually-active and inactive male rats. 18 -21 The reason for this discrepancy is unclear, but it may be related to the difference in strains and age of rats used.
The efficacy of apomorphine in the treatment of erectile dysfunction further supports an involvement of endogenous central dopamine in the control of penile erection. 22 To our knowledge, the impact of selegiline treatment on sexual activity has never been assessed in humans. Nevertheless, the present data suggest that indirect dopaminergic agonists could facilitate sexual response, by specifically enhancing dopaminergic responses at the sites involved in the control of penile erection.
